Positive Results from Disc Medicine's Bitopertin Study in Patients with EPP

Disc Medicine Achieves Success in Mid-Stage Study

The mid-stage study of bitopertin by Disc Medicine has yielded promising results for patients with EPP. Significant reductions in protoporphyrin IX levels were observed, demonstrating the drug's efficacy in treating the condition.

Key Highlights:

• Positive outcomes from bitopertin study
• Statistically significant reductions in protoporphyrin IX
• Meeting the primary goal of the study

This success marks a significant milestone in the development of new treatments for EPP patients.